Patents by Inventor Priscilla Schaffer

Priscilla Schaffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Herpes simplex virus mutant ICP0 protein
    Patent number: 7785605
    Abstract: A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication in order to inhibit phosphorylation of the site so as to prohibit or impair replication of HSV-1 and/or the clinical severity of HSV-1-mediated diseases. The mutant protein can be a mutant ICP0 that has reduced or inhibited posttranslational phosphorylation. The mutant HSV-1 and/or mutant ICP0 can be used in vaccines or other pharmaceutical preparations to treat, limit and/or prevent HSV-1 infection. The mutant HSV-1 and/or mutant ICP0 can also be used in screening and/or developing anti-HSV-1 agents.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: August 31, 2010
    Assignees: University of Kansas, Beth Israel Deaconess Medical Center, Inc.
    Inventors: David Davido, Priscilla Schaffer
  • Methods for treating or preventing reactivation of a latent herpesvirus infection
    Publication number: 20090176743
    Abstract: The invention is directed to methods and compositions for treating or preventing reactivation of a latent herpesvirus infection and the associated complications and outcomes. The methods involve administering a composition comprising glutamine, or a derivative, conjugate, or analog thereof.
    Type: Application
    Filed: July 31, 2006
    Publication date: July 9, 2009
    Inventors: Priscilla Schaffer, Ryan Bringhurst
  • HERPES SIMPLEX VIRUS MUTANT ICP0 PROTEIN
    Publication number: 20090068215
    Abstract: A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication in order to inhibit phosphorylation of the site so as to prohibit or impair replication of HSV-1 and/or the clinical severity of HSV-1-mediated diseases. The mutant protein can be a mutant ICP0 that has reduced or inhibited posttranslational phosphorylation. The mutant HSV-1 and/or mutant ICP0 can be used in vaccines or other pharmaceutical preparations to treat, limit and/or prevent HSV-1 infection. The mutant HSV-1 and/or mutant ICP0 can also be used in screening and/or developing anti-HSV-1 agents.
    Type: Application
    Filed: July 3, 2008
    Publication date: March 12, 2009
    Inventors: DAVID DAVIDO, PRISCILLA SCHAFFER
  • Suppression of cyclin kinase activity for prevention and treatment of infections
    Publication number: 20040254094
    Abstract: The present invention relates to methods for use in treating or preventing infections. More particularly, the invention relates to methods for screening for modulators that inhibit cyclin-dependent kinase and the use of these putative inhibitors to control proliferation of a DNA virus that is dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus.
    Type: Application
    Filed: October 10, 2001
    Publication date: December 16, 2004
    Applicants: The Trustees of University of Pennsylvania and Board of Regents, The University of Texas System
    Inventors: Thomas Albrecht, Laurent Meijer, Priscilla Schaffer, Luis Schang